This is a summary of the European public assessment report (EPAR) for Zostavax. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Zostavax.
Therapeutic Indication
### Therapeutic indication Zostavax is indicated for prevention of herpes zoster ('zoster' or shingles) and herpes-zoster-related post-herpetic neuralgia. Zostavax is indicated for immunisation of individuals 50 years of age or older.
Therapeutic Area (MeSH)
N/AATC Code
J07BK02
ATC Item
zoster, live attenuated
Pharmacotherapeutic Group
Viral vaccines
Active Substance (Summary)
INN / Common Names
N/A| Substance | CAS | Monograph |
|---|---|---|
| varicella-zoster virus (live, attenuated) | N/A | Varicella zoster vaccine (live/attenuated) |
EMA Name
Zostavax
Medicine Name
Zostavax
Aliases
N/ANo risk management plan link.
